Category: Diagnostics
Global Diagnostics
-
X-Ray Photoelectron Spectroscopy
... at a CAGR of 4.8% over the analysis period 2024-2030. Healthcare, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$339.2 Million by the end of the ... Read More
-
Automated Immunoassay Analyzers
... at a CAGR of 4.5% over the analysis period 2024-2030. Immunofluorescence, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
STD Testing
... CAGR of 5.2% over the analysis period 2024-2030. Chlamydia, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$40.6 Billion by the end of the analysis period. ... Read More
-
Tuberculosis Testing
... CAGR of 4.9% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.4 Billion by the end of the analysis period. ... Read More
-
Veterinary Hematology Analyzers
... at a CAGR of 5.3% over the analysis period 2024-2030. Table Top Analyzers, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.2 Billion by the end ... Read More
-
Veterinary Molecular Diagnostics
... at a CAGR of 7.5% over the analysis period 2024-2030. Instruments & Software, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$342.8 Million by the end ... Read More
-
Lung Cancer Diagnostics
... at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Blood Transfusion Devices
... at a CAGR of 5.8% over the analysis period 2024-2030. Pathogen Reduction System, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.7 Billion by the end ... Read More
-
Cardiac POC Testing Devices
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Cardiac Markers Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.6 Billion by ... Read More
-
Clostridium Diagnostics
... CAGR of 14.2% over the analysis period 2024-2030. Immunoassays, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$9.1 Billion by the end of the analysis period. ... Read More
-
Contrast Injectors
... CAGR of 4.5% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$470.8 Million by the end of the analysis period. ... Read More
-
Dental Digital X-ray
... at a CAGR of 5.9% over the analysis period 2024-2030. Extraoral, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Enteric Disease Testing
... at a CAGR of 4.9% over the analysis period 2024-2030. Bacterial Enteric Disease, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.8 Billion by the end ... Read More
-
Blood Banking and Blood Products
... Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Blood Components & Plasma Products, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and ... Read More
-
Fluoroscopy and Mobile C-Arms
... 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Fluoroscopy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end ... Read More
-
Molecular Diagnostics
... CAGR of 9.2% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$16.0 Billion by the end of the ... Read More
-
Analytical Laboratory Services
... at a CAGR of 9.0% over the analysis period 2024-2030. Bioanalytical Testing, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$273.4 Million by the end of ... Read More
-
Anatomic Pathology
... CAGR of 5.8% over the analysis period 2024-2030. Disease Diagnostics, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$53.0 Billion by the end of the analysis ... Read More
-
Blood Screening
... CAGR of 5.5% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.7 Billion by the end of the ... Read More
-
Breast Imaging Technologies
... at a CAGR of 5.2% over the analysis period 2024-2030. Ionizing Technologies, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.3 Billion by the end of ... Read More
-
Carrier Screening
... CAGR of 15.6% over the analysis period 2024-2030. Genetic Disorders, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.0 Billion by the end of the analysis ... Read More
-
Pneumonia Therapeutics
... CAGR of 6.7% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$6.8 Billion by the end of the analysis period. ... Read More
-
Veterinary Diagnostics
... CAGR of 7.0% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.6 Billion by the end of the analysis period. ... Read More
-
Antithrombin
... 5.3% over the analysis period 2024-2030. Therapeutics, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$847.5 Million by the end of the analysis period. Growth in ... Read More
-
Blood Transfusion Diagnostics
... at a CAGR of 4.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.7 Billion by the end of the ... Read More